Summary
BMF Reports published a critical report titled “The Placebo Hustle,” alleging INmune Bio (NASDAQ: INMB) is exaggerating the promise of its lead drug candidate, XPro. The report claims INmune Bio is advancing a previously abandoned drug through clinical stages with misleading trial interpretations, while facing severe financial strain.
Who is INmune Bio?
INmune Bio is a clinical-stage immunology company focused on leveraging the innate immune system to treat chronic inflammation, cancer, and neurodegenerative diseases. The company’s primary asset, XPro, a dominant-negative TNF inhibitor, is currently in Phase 2 trials for early Alzheimer’s Disease. INmune Bio also maintains a pipeline targeting natural killer (NK) cell therapies and other inflammatory conditions. Despite years in development, the company has yet to report consistent, statistically significant efficacy results in large trials.
Key Points from Report
A Clinical Stage “Circus”
- BMF Reports argues that INmune Bio’s XPro program is built on weak science and inconclusive data, pointing to its origins as an abandoned drug now repurposed for Alzheimer’s.
- The Phase 2 MINDFuL trial enrolled 208 patients, but failed to meet primary endpoints in the broader modified intent-to-treat group.
Overstated Subgroup Signals
- Only a biomarker-defined subgroup (~100 patients) showed modest improvement, with an EMACC effect size of 0.27 and a small reduction in pTau217 levels.
- Despite this, the company promoted the results as significant and transformational, raising concerns over selective reporting ahead of presentations at key scientific conferences.
Bleak Financial Position
- INmune Bio reported a $42.1 million net loss in 2024, a sharp increase from $30 million the year prior.
- As of year-end, the company had just $20.9 million in cash—enough to fund operations into the third quarter of 2025 unless additional capital is raised.
- A recent $19 million raise through an ATM facility may delay the cash crunch, but it remains insufficient to fund future phases or commercialization.
High Short Interest and Analyst Downgrades
- Approximately 49% of the float is currently shorted, with a 16.8-day short interest ratio—one of the highest in the biotech sector.
- Analysts have expressed concern, with some issuing price targets near zero and categorizing the stock as a speculative bet rather than an investment backed by solid data.
Activ8 Finance Analysis
BMF’s report highlights serious doubts about INmune Bio’s clinical rigor, financial health, and transparency. The mixed Phase 2 results raise questions about whether XPro can advance meaningfully without selective data interpretation or aggressive marketing. Compounding this is a short cash runway and heavy insider ownership, suggesting potential misalignment with retail investors. The exceptionally high short interest indicates broad skepticism within institutional circles. Until INmune Bio delivers unambiguous, replicated efficacy in broader populations, its valuation may reflect hope rather than proven therapeutic promise.